BRPI0406789A - Composição farmacêutica e métodos de intensificação de expressão do fator-2 do trefoil (tff2), de avaliação fisiológica pulmonar, de tratamento e de intensificação da restauração de tecido inflamado induzido por alérgeno - Google Patents

Composição farmacêutica e métodos de intensificação de expressão do fator-2 do trefoil (tff2), de avaliação fisiológica pulmonar, de tratamento e de intensificação da restauração de tecido inflamado induzido por alérgeno

Info

Publication number
BRPI0406789A
BRPI0406789A BR0406789-4A BRPI0406789A BRPI0406789A BR PI0406789 A BRPI0406789 A BR PI0406789A BR PI0406789 A BRPI0406789 A BR PI0406789A BR PI0406789 A BRPI0406789 A BR PI0406789A
Authority
BR
Brazil
Prior art keywords
tff2
allergen
trefoil factor
treatment
pharmaceutical composition
Prior art date
Application number
BR0406789-4A
Other languages
English (en)
Inventor
Marc Elliot Rothenberg
Original Assignee
Childrens Hosp Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hosp Medical Center filed Critical Childrens Hosp Medical Center
Publication of BRPI0406789A publication Critical patent/BRPI0406789A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA E MéTODOS DE INTENSIFICAçãO DA EXPRESSãO DO FATOR-2 DO TREFOIL (TFF2), DE AVALIAçãO FISIOLóGICA PULMONAR, DE TRATAMENTO E DE INTENSIFICAçãO DA RESTAURAçãO DE TECIDO INFLAMADO INDUZIDO POR ALéRGENO". Composição e método de alívio da resposta alérgica por regulação da expressão do fator-2 do trefoil (TFF2). O TFF2 é também revelado como um marcador para avaliação do estado do paciente alérgico, por exemplo, monitorando a inflamação e/ou restauração tecidular no pulmão do paciente asmático. A regulação do TFF2 está envolvida na patogênese da inflamação pulmonar alérgica e outras condições induzidas por alergêneo, por exemplo, a sobrerregulação do TFF2 pode exercer um efeito protetor pela redução da secreção ácida e/ou aumento da proliferação celular epitelial, de modo a promover a cura.
BR0406789-4A 2003-01-17 2004-01-16 Composição farmacêutica e métodos de intensificação de expressão do fator-2 do trefoil (tff2), de avaliação fisiológica pulmonar, de tratamento e de intensificação da restauração de tecido inflamado induzido por alérgeno BRPI0406789A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44093403P 2003-01-17 2003-01-17
PCT/US2004/001140 WO2004064860A1 (en) 2003-01-17 2004-01-16 Use of tff2, or agents inducing tff2, in the therapy of allergies

Publications (1)

Publication Number Publication Date
BRPI0406789A true BRPI0406789A (pt) 2006-01-17

Family

ID=32771879

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406789-4A BRPI0406789A (pt) 2003-01-17 2004-01-16 Composição farmacêutica e métodos de intensificação de expressão do fator-2 do trefoil (tff2), de avaliação fisiológica pulmonar, de tratamento e de intensificação da restauração de tecido inflamado induzido por alérgeno

Country Status (7)

Country Link
US (1) US20040209806A1 (pt)
EP (1) EP1587534A1 (pt)
JP (1) JP2006516035A (pt)
AU (1) AU2004206868A1 (pt)
BR (1) BRPI0406789A (pt)
CA (1) CA2512709A1 (pt)
WO (1) WO2004064860A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525018B1 (en) 1999-05-17 2003-02-25 The General Hospital Corp. Treating eye disorders using intestinal trefoil proteins
US7538082B2 (en) 2001-04-24 2009-05-26 The General Hospital Corporation Methods and compositions for treating oral and esophageal lesions
ES2393197T3 (es) 2004-09-28 2012-12-19 Otsuka Pharmaceutical Co., Ltd. Compuesto de carbostirilo
WO2011106702A2 (en) 2010-02-25 2011-09-01 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
BR112012030930A2 (pt) * 2010-06-04 2017-07-11 Trifoilium Aps fatores de trevo (tff) para tratamento de doenças pulmonares crônicas.
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
AU2013232297B2 (en) 2012-03-16 2016-01-14 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
WO2013138346A1 (en) 2012-03-16 2013-09-19 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
EP3250184A1 (en) 2015-01-27 2017-12-06 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5010793A (en) * 1992-08-21 1994-03-15 Schering Corporation Human interleukin-13
MY124565A (en) * 1996-07-19 2006-06-30 Bayer Corp High-affinity interleukin-4-muteins
GB9625899D0 (en) * 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
DK1141286T3 (da) * 1998-12-14 2007-02-19 Genetics Inst Llc Kæde af cytokinreceptorer
WO2002102399A2 (en) * 2001-06-14 2002-12-27 Novo Nordisk A/S Mucosal repair by tff2 peptides
EP1438062A4 (en) * 2001-10-05 2005-06-01 Gen Hospital Corp METHOD AND COMPOSITIONS FOR TREATING SKIN Lions
JP2005532988A (ja) * 2001-11-28 2005-11-04 ザ ジェネラル ホスピタル コーポレーション 呼吸上皮の病変を治療するための方法および組成物

Also Published As

Publication number Publication date
JP2006516035A (ja) 2006-06-15
US20040209806A1 (en) 2004-10-21
EP1587534A1 (en) 2005-10-26
WO2004064860A8 (en) 2004-10-21
WO2004064860A1 (en) 2004-08-05
AU2004206868A1 (en) 2004-08-05
CA2512709A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
BRPI0406789A (pt) Composição farmacêutica e métodos de intensificação de expressão do fator-2 do trefoil (tff2), de avaliação fisiológica pulmonar, de tratamento e de intensificação da restauração de tecido inflamado induzido por alérgeno
Xu et al. A critical assessment of the fibula flap donor site
Levinger et al. Asymmetric knee loading at heel contact during walking in patients with unilateral knee replacement
JPH0441431A (ja) 局所投与用抗アレルギー剤
CN105920094A (zh) 一种鼻腔护理组合物、其用途以及所得的鼻腔护理产品
RU2354367C1 (ru) Способ комплексного консервативного лечения остеоартроза ранних стадий крупных суставов и способ его оценки
CN101229263B (zh) 一种治疗牛皮癣的中药
Sohi et al. Apert's syndrome
Amin et al. External Perforating Push Out Lateral Osteotomies for Treatment of Crooked Nose
BRPI0406776A (pt) Composição farmacêutica, método de avaliação fisiológica e uso de pelo menos um dentre um inibidor de uma molécula semelhante a resistina (alfa) (relm(alfa)), uma molécula semelhante a resistina ß (relmß), um regulador de expressão de relm(alfa) ou um regulador de expressão de relmß
Tampouratzi et al. 40482 Early treatment intervention in moderate psoriasis keeps a long-term remission among patients with apremilast: a single-center observational study with 5 years data
Liu et al. 42138 Effect of a novel witch hazel formula on skin barrier health
Benedicto-Maldonado et al. 43986 Effectiveness in real world practice after fifty-two weeks of Risankizumab treatment for patients with moderate-to-severe psoriasis: thirty-one patient cohort
CN1316987C (zh) 治疗颈腰椎关节炎的膏药
Insel et al. 41991 Early skin surface biomarkers associated with risk susceptibility to atopic dermatitis in children with family history of allergic disease
Morrison et al. 038 Validation of the Priapism Profile Impact Questionnaire
Khan et al. Comparison of biophysical variables among psoriatic patients based on the Psoriasis Area and Severity Index (PASI) groups
Ridlon Studies on Leptospira icterohemorrhagiae
Arya et al. Role of Agnikarma in the Management of Plantar Fasciitis
Guslandi et al. Lack of effect of ambroxol, a bronchial secretolytic agent, on gastric mucus in man
Mahajan et al. Clinico-radiological outcome of distal radius fractures managed with closed reduction during COVID-19 pandemic
Kituashvili et al. Research Article Efficacy of Lazolex® Gel in the Treatment of Herpes Simplex Mucocutaneous Infections and the Prevention of Recurrences: A Pilot Study
Henderson Abuse of Ephedrine
CN111714536A (zh) 一种接骨膏药
Zafar et al. Volkmann’s ischemic contracture: a late complication of snakebite

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]